The Cross-Border Biotech Blog

Catch up on all the Canadian biotech news that caught our eyes this week:

• CAMH out-licenses to Athena Diagnostics in MA to develop genetic test for muscle disorders caused by FHL1 mutations http://bit.ly/cTSUrd 
• Ontario Hospital Association & PharmaTrust Partner on telepharmacy prescription-dispensing kiosks in hospitals http://bit.ly/c0wlXG 
• Congrats to winners of CNA-CMA 2010 Media Awards for Health Reporting! http://bit.ly/93w1E0
• RT @CLSD: Congrats to Calgary’s Resverlogix – Additional $8 million in financing brings them up to $38 M in 2 mnths. http://zlig.ca/o9bG4
• RT @matthewherper: Why limiting speaking fees for academics may lead to more non-academic pharma experts: http://bit.ly/9s4uwR
• New Post: Biotech Trends Update: Jubilant’s R&D Success Continues Drive Toward Innovation in Asia http://ow.ly/16ryWm 
• RT @naturebiotech: Another extension on the SBIR program. Biotech waits for a decision on companies majority owned by VCs… 
• RT @SternIR: $GENZ new incentive comp plan metrics – operating income and “key business objectives” http://bit.ly/a2CIAv (details in 8-K) 
• RT @robannan: New blog post: Can Canada keep up? http://bit.ly/cwnQWm
• Cool.Confidential? RT @jordan_law21: An iPhone-based free legal research tool: http://bit.ly/a4YAsT .We have officially left Kansas. #slawca
• So much for commandment 10 RT @adamfeuerstein: AAPL Has there been this much anticipation about a tablet since Moses walked off Mt. Sinai?
• RT @JohnCFierce: The prolific Corey Goodman is popping up yet again, in a VC outfit. http://bit.ly/bHOgZe 
• New Post: Current Data on the State of Biotech in Canada – Equicom published a report recently that takes a compreh… http://ow.ly/16qW2j
• RT @CVCACanada: CDPQ & Desjardins join forces to invest add. $600M in Québec SMBs http://bit.ly/aIKxjV
• RT @startupcfo: RT @bwat: Terence Matthews plans $100-million fund to fill Nortel void <– Canada needs it! http://icio.us/hun2l3
• RT @FDAcdrhIndustry: Premarket Approvals (PMA) for 12/09 http://bit.ly/7kq64H #FDA 
• New Post: Boosting Canadian Commercialization at the Ontario Institute of Cancer Research http://ow.ly/16qsxP
• RT @PharmProEditor: YM BioSciences Announces #FDA Clearance for Two Ongoing Phase II Nimotuzumab Trials into USA http://bit.ly/8sV7Bt 
• RT @genomicslawyer @patsycat21: Pediatric cancer genome project will sequence tumors from 600 children: http://tr.im/LyZL 
• RT @CLSD: Biotech industry starts 2010 on upbeat note as survey reveals improved cash situation for firms http://bit.ly/4JNwNo 
• RT @jonmrich: “How Google and Bing Plan to Eliminate the Need for WebMD (and Your Website)” Latest Dose of Digital. Plz RT http://bit.ly/7pg69g 
• RT @ogilvyrenault: Conference: Green Energy Act Finance Forum, Jan.29, Toronto. Details – http://bit.ly/5×7qyc 11:49 AM Jan 25th from TweetDeck
• RT @MaRSDD: Blog: Canadians support medical spending – is government listening? http://ow.ly/10g36  
• @rogerchabra congrats on the new gig! “Roger Chabra Joins Rho Canada as a Partner” http://bit.ly/4ufX56
• RT @nih_nhlbi: New Recovery Act funds available! NIH accepting proposals for Comparative Effectiveness Research staff http://bit.ly/4K0chU 
• Press release & link to full report via @Equicom‘Survival, Success and Surrender’ in the Canadian healthcare sector: http://bit.ly/7XcFzN 
• MDS ($MDS $MDZ) says PerkinElmer ($PKI) agreed to terminate its litigation re MDS Analytical Tech sale. No $ disclosed. http://bit.ly/74ndTJ 
• Æterna Zentaris ($AEZ $AEZS) reports Phase 2 results via partner Keryx ($KERX) , kicks $AEZS stock price back over $1 http://bit.ly/81w73q 
• RT @SternIR: VC firm SV Life Sciences raises 5th fund of $400MM, 50% allocated to biotech; 70-75% to be invested in US